Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alogliptin SCHEMBL121028 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL29352995 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL174188 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL475872 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17781892 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL23712233 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL391800 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL28406504 | 0.95 | DPP4 (0.91) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL1071798 | 0.94 | DPP4 (0.91) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476232 | 0.93 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110684-A | Compositions containing a mixture of pyrimidinedione derivatives and uses thereof | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111110684-A | Compositions containing a mixture of pyrimidinedione derivatives and uses thereof | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| EP-2885302-B1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-9776985-B2 | Process for preparation of alogliptin | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-10-03 | — | — | US | disclosed |
| US-9776985-B2 | Process for preparation of alogliptin | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-10-03 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| US-9593119-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9593119-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-20160340333-A1 | PROCESS FOR PREPARATION OF ALOGLIPTIN | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| US-20160340333-A1 | PROCESS FOR PREPARATION OF ALOGLIPTIN | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| US-20160272642-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272642-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-09-22 | — | — | US | disclosed |
| US-9353114-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9353114-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| WO-2016046679-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK GENERICS LIMITED (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK GENERICS LIMITED (IN) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | DPP4, DPP9, DPP3 | DPP4 1/4885OPRM1 2763/4885OPRK1 2267/4885 |
| US-20160272642-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | DPP9, DPP4, DPP7 | DPP4 2/4885OPRM1 3672/4885OPRK1 3140/4885 |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885OPRM1 1224/4885OPRK1 1227/4885 |
| US-20160340333-A1 | PROCESS FOR PREPARATION OF ALOGLIPTIN | DPP4, DPP7, DPP8 | DPP4 1/4885OPRM1 2417/4885OPRK1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.